Today, Feb. 23, 2026, a pivotal obesity‑drug trial setback forces investors to rethink Novo Nordisk’s strategy.
Today’s Change
(-16.33%) $-7.75
Current Price
$39.67
Key Data Points
Market Cap
$134B
Day’s Range
$39.34 – $41.09
52wk Range
$39.34 – $93.80
Volume
3.7M
Avg Vol
23M
Gross Margin
80.90%
Dividend Yield
4.36%
Novo Nordisk (NVO 16.33%), a healthcare giant that develops and markets diabetes and obesity treatments, closed Monday at $39.63, down 16.43%. The stock fell after it announced CagriSema, its next-generation obesity drug, had not fared well in a head-to-head trial.
Trading volume reached 94.9 million shares, about 343% above its three-month average of 21.4 million shares. Novo Nordisk IPO’d in 1981 and has grown 24,669% since going public.
How the markets moved today
The S&P 500 (^GSPC 1.04%) slipped 1.04% to 6,838, while the Nasdaq Composite (^IXIC 1.13%) fell 1.13% to finish at 22,627. Among pharmaceutical peers, Eli Lilly (LLY +4.86%) closed at $1,058.456, up 4.86%, while Novartis (NVS +1.25%) gained 1.25% to end at $164.70, as investors reassessed obesity‑drug leaders.
What this means for investors
Novo Nordisk’s dramatic drop sent the stock to its lowest point since 2021, wiping out gains from its Wegovy weight-loss drug. The stock, which peaked in 2024, was already struggling after initial data for CagriSema disappointed.
Today’s announcement showed the drug did not come out on top in a direct comparison with Eli Lilly’s tirzepatide. People taking CagriSema achieved 23% weight loss after 84 weeks of treatment, compared with 25.5% for tirzepatide. Deutsche Bank (DB 1.99%) downgraded Novo from “Buy” to “Hold” following the trial results.
Earlier this month, Novo shares dropped after the company warned that 2026 sales could decline by 5% to 13%. Investors are now questioning Novo Nordisk’s strategy and will be watching to see if it can expand beyond diabetes and obesity drugs.
